{"id":61432,"date":"2024-02-28T07:40:41","date_gmt":"2024-02-28T07:40:41","guid":{"rendered":"https:\/\/medsname.com\/mefque\/"},"modified":"2026-04-30T10:23:35","modified_gmt":"2026-04-30T10:23:35","slug":"mefque","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/mefque\/","title":{"rendered":"Mefque"},"content":{"rendered":"

<\/p>\n

\n

Snelle antwoord<\/h3>\n

Mefque<\/strong> bevat mefloquine 250 mg<\/strong> (Cipla). It is a once-weekly chemoprophylaxis option for chloroquine-resistant malaria<\/strong> in sub-Saharan Africa, India, Southeast Asia (excluding the Thai-Cambodia \/ Thai-Myanmar borders), and the Amazon. Adult dose: 250 mg once weekly, started 2\u20133 weeks before travel<\/strong> (to identify intolerance and reach steady state), continued during travel, and continued 4 weeks after return<\/strong>. Take with a full meal and water. Mandatory pre-travel test dose 3 weeks before departure<\/strong> \u2014 if neuropsychiatric side effects occur, switch to doxycycline or atovaquone-proguanil before flying. Contraindicated in patients with current or past depression, generalised anxiety disorder, psychosis, schizophrenia, bipolar disorder, seizure disorders, or significant cardiac conduction abnormality.<\/p>\n<\/div>\n

\ud83c\udfed WHO-GMP gecertificeerde fabrikant<\/strong>  \u00b7  \ud83d\udce6 Discrete verpakking<\/strong>  \u00b7  \ud83c\udf0d Wereldwijde verzending<\/strong>  \u00b7  \u2b50 1.400+ klantbeoordelingen<\/a><\/strong><\/div>\n

\ud83d\udee1\ufe0f Elke bestelling wordt gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij een gratis vervanging via EMS of ITPS koerier.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Mefque is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our Reshipment Assurance Policy<\/a> en ondersteund door onze 1.400+ klantbeoordelingen<\/a>. Wereldwijde verzending zonder receptpapieren.<\/p>\n

About Mefque<\/h2>\n

Mefque is a 250 mg mefloquine hydrochloride tablet manufactured by Cipla under WHO-GMP certified conditions. Mefloquine was developed by the US Walter Reed Army Institute of Research in the 1970s and remains one of the three modern options (with doxycycline and atovaquone-proguanil) for prophylaxis in chloroquine-resistant areas. Its long half-life enables once-weekly dosing \u2014 convenient on long trips.<\/p>\n

How mefloquine works<\/h2>\n

Mefloquine is a 4-quinolinemethanol antimalarial. Like chloroquine it interferes with parasite haem detoxification in the food vacuole, but is active against many chloroquine-resistant strains because it does not depend on the same parasite transport mechanism. It also has activity against blood-stage P. falciparum, P. vivax, P. ovale, and P. malariae. Mefloquine has substantial CNS penetration \u2014 desirable for parasitological efficacy, but the source of its neuropsychiatric side-effect profile.<\/p>\n

Half-life is ~ 2\u20133 weeks. Once-weekly dosing reaches steady state by week 7\u20139; this is why most authorities recommend a 2\u20133 week pre-travel start.<\/p>\n

Indicaties en dosering<\/h2>\n
\n\n\n\n\n\n\n\n\n
Indicatie<\/th>\nDosering<\/th>\nSchema<\/th>\n<\/tr>\n<\/thead>\n
Chemoprophylaxis, adult<\/td>\n250 mg once weekly<\/td>\nStart 2\u20133 weeks before entering malaria area; continue weekly during exposure; continue 4 weeks after return.<\/td>\n<\/tr>\n
Paediatric chemoprophylaxis (\u2265 5 kg)<\/td>\n5 mg\/kg once weekly (max 250 mg)<\/td>\nSame start \/ continue \/ stop schedule. Halved tablet for smaller children \u2014 exact mg\/kg matters.<\/td>\n<\/tr>\n
Acute uncomplicated chloroquine-resistant P. falciparum malaria, adult<\/td>\n750 mg single dose, then 500 mg 6\u201312 h later (1 250 mg total)<\/td>\nTreatment doses cause significantly more side effects than prophylactic doses. Modern WHO preference is artemisinin combination therapy where available.<\/td>\n<\/tr>\n
Standby emergency self-treatment of presumptive malaria<\/td>\n750 mg + 500 mg as above<\/td>\nFor travellers in areas without rapid medical access who develop a febrile illness compatible with malaria. Not a substitute for medical evaluation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
Neuropsychiatric red-box \u2014 read before purchase.<\/strong> Mefloquine is associated with anxiety, vivid dreams, nightmares, insomnia, mood change, depression, suicidal ideation, paranoia, hallucinations, and rare seizures. Most reactions occur within the first 3 doses. Some patients describe long-lasting (“post-mefloquine syndrome”) symptoms after the drug is stopped. Contraindicated in:<\/strong> current or past depression, generalised anxiety disorder, psychosis, schizophrenia, bipolar disorder, seizure disorder, severe cardiac conduction abnormality, recent traumatic brain injury, history of severe psychiatric illness in close family. Always do a 3-week pre-travel test dose<\/strong>: if anxiety, dysphoria, vivid dreams, or sleep disturbance develop, switch to doxycycline or atovaquone-proguanil before flying.<\/div>\n
Cardiac note.<\/strong> Mefloquine prolongs PR interval and modestly prolongs QTc. Avoid combination with other QT-prolonging drugs (azithromycin, ondansetron, fluoroquinolones, antipsychotics, SSRIs \/ TCAs at high dose). Avoid in patients with bradycardia, AV-block, or pacemaker dependence without cardiology consultation.<\/div>\n

Bijwerkingen<\/h2>\n